Registries offer insights which helps clinicians and institutions to improve the delivery of healthcare. They also act as a tool for pharmaceutical companies to gather evidence of their drugs’ effectiveness for approved indications and potentially new indications, thus encouraging further research.
Data collected by the Save Sight Registries provide benefits for our patients and other stakeholders.
Patient Level
Graphs of long-term treatment outcomes and progression of eye diseases can be generated in real-time by clinicians and shown to patients.
Doctor or Practice Level
Reports charting patient progress (individual eyes treated) can be generated simply with the click of a button and enable clinicians to track real-time outcomes at the individual patient or clinic level
- It allows clinicians to conduct self-audits
- Improve patient flow
- Gain CPD points
Patient and the Health System
Encourages scientific collaboration and dissemination of key clinical findings
Testimonials
“From my perspective FRB! System has been a real God send. Without FRB! I would not be able to follow the progress (or lack of!) or audit the seemingly hundreds of patients who are under my care within the public system”
“This data is Gold! Thank you so much”
“There is a growing head of steam recognising the worth of FRB! as a tool to provide the ongoing outcome audit we so desperately need here”
“Thank you very much for your comprehensive introduction to the FRB project…. The practical and scientific values of the project has become clear to us as well as easiness of data entry (just a few seconds!)”
“Thanks a lot for the interim report, which is very comprehensive and inspiring”
Publications
| Title | Publications | Date Published | Link |
|---|---|---|---|
Type 3 neovascularisation (retinal angiomatous proliferation) treated with anti-vascular endothelial growth factor: real world outcomes at 24 months | British Journal of Ophthalmology | 2019 September | https://www.ncbi.nlm.nih.gov/pubmed/30504490/ |
Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months | Ophthalmology Retina | 2019 August | https://www.ncbi.nlm.nih.gov/pubmed/31281103 |
Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project | American Journal of Ophthalmology | 2019 August | https://www.ncbi.nlm.nih.gov/pubmed/30862501 |
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents | Ophthalmology | 2019 May | https://www.ncbi.nlm.nih.gov/pubmed/30529685 |
A multi-country comparison of real world management and outcomes of polypoidal choroidal vasculopathy – Fight Retinal Blindness! Cohort | Ophthalmology Retina | 2019 March | https://www.ncbi.nlm.nih.gov/pubmed/31014698 |
Assessing the accuracy of a large observational registry of neovascular age-related macular degeneration | Retina | 2019 February (epub) | https://www.ncbi.nlm.nih.gov/pubmed/30821728 |
Projection of long-term visual outcomes based on initial treatment response in neovascular age-related macular degeneration | Ophthalmology | 2019 January | https://www.ncbi.nlm.nih.gov/pubmed/30149035 |
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents | Ophthalmology | 2018 December (epub) | https://www.ncbi.nlm.nih.gov/pubmed/30529685 |
Type 3 neovascularisation (retinal angiomatous proliferation) treated with anti-vascular endothelial growth factor: real world outcomes at 24 months | British Journal of Ophthalmology | 2018 December (epub) | https://www.ncbi.nlm.nih.gov/m/pubmed/30504490/ |
A multi-country comparison of real world management and outcomes of polypoidal choroidal vasculopathy – Fight Retinal Blindness! Cohort | Ophthalmology Retina | 2018 November (epub) | https://www.sciencedirect.com/science/article/abs/pii/S2468653018303142 |
Trainee-led vs. specialist-led management of neovascular age-related macular degeneration. A registry-based study. | British Journal of Ophthalmology | 2018 November (epub) | https://www.ncbi.nlm.nih.gov/pubmed/30385435 |
Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: data from an observational study | Retina | 2018 October | https://www.ncbi.nlm.nih.gov/pubmed/28820848 |
A Pharmacoepidemiologic Study of | Graefe’s Archive for Clinical and Experimental Ophthalmology | 2018 October | https://www.ncbi.nlm.nih.gov/pubmed/30051312 |
Projection of long-term visual outcomes based on initial treatment response in neovascular age-related macular degeneration | Ophthalmology | 2018 August (epub) | https://www.ncbi.nlm.nih.gov/pubmed/30149035 |
Outcomes and predictive factors after cataract | American Journal of Ophthalmology | 2018 June | https://www.ncbi.nlm.nih.gov/pubmed/29550186 |
Outcomes in neovascular age-related macular degeneration when neovascular lesion activity uncertain: observational study | Ophthalmology Retina | 2018 June | https://www.sciencedirect.com/science/article/pii/S2468653017304219 |
Clinical and social characteristics associated | Clinical and Experimental Ophthalmology | 2018 April | https://www.ncbi.nlm.nih.gov/pubmed/28842956 |
Early and late retinal pigment epithelial tears | Ophthalmology | 2018 February | https://www.ncbi.nlm.nih.gov/pubmed/28993010 |
Incidence and outcomes of infectious and noninfectious endophthalmitis following intravitreal injections for age-related macular | Ophthalmology | 2018 January | https://www.ncbi.nlm.nih.gov/pubmed/28801117 |
Two Year Outcomes of “Treat and Extend” | Retina | 2018 January | https://www.ncbi.nlm.nih.gov/pubmed/28145976 |
Outcomes in neovascular age-related macular | Ophthalmology Retina | 2017 December (Epub) | https://www.sciencedirect.com/science/article/pii/S2468653017304219 |
Ranibizumab and aflibercept for the treatment | Retina | 2017 August (Epub) | https://www.ncbi.nlm.nih.gov/pubmed/28820848 |
Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) | Ophthalmology | 2017 March | https://www.ncbi.nlm.nih.gov/pubmed/28219517 |
Seven-year trends in visual acuity at first | Ophthalmology | 2017 February | https://www.ncbi.nlm.nih.gov/pubmed/27596290 |
Twelve-month outcomes of ranibizumab vs. | Ophthalmology | 2016 December | https://www.ncbi.nlm.nih.gov/pubmed/27707549 |
Effects of Switching from Ranibizumab to | British Journal of Ophthalmology | 2016 December | http://www.ncbi.nlm.nih.gov/pubmed/26994110 |
Treatment patterns and visual outcomes during | Ophthalmology | 2016 November | http://www.ncbi.nlm.nih.gov/pubmed/27554034 |
Long-term outcomes of treatment of | Ophthalmology | 2015 September | https://www.ncbi.nlm.nih.gov/pubmed/26096346 |
Two Year Outcomes of “Treat And Extend” | Ophthalmology | 2015 June | https://www.ncbi.nlm.nih.gov/pubmed/25846847 |
Time to initial clinician-reported inactivation of | Ophthalmology | 2015 March | https://www.ncbi.nlm.nih.gov/pubmed/25458197 |
Outcomes of persistently active neovascular age | British Journal of Ophthalmology | 2015 March | https://www.ncbi.nlm.nih.gov/pubmed/25249615 |
Intravitreal Therapy in Bilateral Neovascular | Ophthalmology | 2014 October | http://www.ncbi.nlm.nih.gov/pubmed/24939512 |
Reasons for discontinuation of intravitreal | Retina | 2014 September | https://www.ncbi.nlm.nih.gov/pubmed/24837049 |
Consequences of long-term discontinuation of | Acta Ophthalmologica | 2014 April | https://onlinelibrary.wiley.com/doi/full/10.1111/aos.12417 |
Comparison of Outcomes from a Phase 3 Study | Ophthalmology | 2014 March | https://www.ncbi.nlm.nih.gov/pubmed/24290801 |
Efficient capture of high quality data on | Retina | 2014 January | https://www.ncbi.nlm.nih.gov/pubmed/23836194 |
Prospective Audit of Exudative Age-Related Macular Degeneration: 12-month Outcomes in Treatment-Naïve eyes. | Investigative Ophthalmology and Visual Science | 2013 August | http://iovs.arvojournals.org/article.aspx?articleid=2128922 |